Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Holding EDIT?
Track your performance easily
EDIT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.70 - $11.69
Previous Close$3.3
Volume1.51M
Average Volume (3M)1.96M
Market Cap
$272.41M
Enterprise Value$45.81M
Total Cash (Recent Filing)$265.09M
Total Debt (Recent Filing)$38.49M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Feb 26, 2025EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding82,548,099
10 Day Avg. Volume2,404,785
30 Day Avg. Volume1,964,926
Standard Deviation0.28
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.55
Price to Sales (P/S)4.17
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit0.59
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$9.08Price Target Upside195.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Editas Medicine News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMarket is valuing the stock at just $260M, $62M below cash, indicating a potential undervaluation.
Medical Advancements100% of patients were VOE-free post-reni-cel infusion, compared to a mean of 4.9 severe VOEs/year in the 2 years before enrollment.
Strategic PartnershipsThe development of extrahepatic in vivo assets will be done in collaboration with Genevant, noting up to $238 million in upfront and contingent payments.
Bears Say
Competitive PressureResearch and development spending was below analyst and consensus expectations, indicating possible concerns about resource allocation.
Financial PerformanceThird quarter revenue was significantly below consensus estimates, reporting at $0.1M compared to the expected $7.1M.
Strategic ConcernsThe cost for developing and commercializing reni-cel is too much for a standalone investment.
---
Ownership Overview
0.94% Insiders
16.68% Mutual Funds
1.43% Other Institutional Investors
66.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EDIT FAQ
What was Editas Medicine Inc’s price range in the past 12 months?
Editas Medicine Inc lowest stock price was $2.70 and its highest was $11.69 in the past 12 months.
What is Editas Medicine Inc’s market cap?
Currently, no data Available
When is Editas Medicine Inc’s upcoming earnings report date?
Editas Medicine Inc’s upcoming earnings report date is Feb 26, 2025 which is in 105 days.
How were Editas Medicine Inc’s earnings last quarter?
Editas Medicine Inc released its earnings results on Nov 04, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.747 by -$0.003.
Is Editas Medicine Inc overvalued?
According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued.
Does Editas Medicine Inc pay dividends?
Editas Medicine Inc does not currently pay dividends.
What is Editas Medicine Inc’s EPS estimate?
Editas Medicine Inc’s EPS estimate is -$0.36.
How many shares outstanding does Editas Medicine Inc have?
Editas Medicine Inc has 82,548,096 shares outstanding.
What happened to Editas Medicine Inc’s price movement after its last earnings report?
Editas Medicine Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.747. Following the earnings report the stock price went down -1.031%.
Which hedge fund is a major shareholder of Editas Medicine Inc?
Among the largest hedge funds holding Editas Medicine Inc’s share is Woodline Partners LP. It holds Editas Medicine Inc’s shares valued at 5M.
---
Editas Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.08 (195.77% Upside)
$9.08 (195.77% Upside)
Blogger Sentiment
Bullish
EDIT Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.97%
12-Months-Change
Fundamentals
Return on Equity
-78.56%
Trailing 12-Months
Asset Growth
-35.09%
Trailing 12-Months
Company Description
Editas Medicine Inc
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
---
EDIT Earnings Call
Q2 2024
0:00 / 0:00
---
EDIT Stock 12 Month Forecast
Average Price Target
$9.08
▲(195.77% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering EDIT
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
-1.29%
reiterated a buy rating 9 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -1.29% per trade.
---